11,939 Shares in MiMedx Group, Inc. (NASDAQ:MDXG) Acquired by Ameriprise Financial Inc.

Ameriprise Financial Inc. bought a new position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,939 shares of the company’s stock, valued at approximately $115,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MDXG. Jane Street Group LLC raised its stake in shares of MiMedx Group by 26.2% during the fourth quarter. Jane Street Group LLC now owns 385,594 shares of the company’s stock worth $3,709,000 after purchasing an additional 79,942 shares during the last quarter. Connors Investor Services Inc. grew its holdings in MiMedx Group by 23.4% in the fourth quarter. Connors Investor Services Inc. now owns 24,676 shares of the company’s stock valued at $237,000 after purchasing an additional 4,676 shares during the last quarter. First Light Asset Management LLC acquired a new stake in MiMedx Group in the fourth quarter valued at $32,168,000. Northern Trust Corp lifted its position in shares of MiMedx Group by 11.4% in the fourth quarter. Northern Trust Corp now owns 1,199,970 shares of the company’s stock valued at $11,544,000 after acquiring an additional 123,205 shares in the last quarter. Finally, Tudor Investment Corp ET AL purchased a new stake in shares of MiMedx Group in the fourth quarter valued at $576,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Insider Transactions at MiMedx Group

In other news, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the sale, the insider now owns 310,836 shares in the company, valued at approximately $2,452,496.04. This trade represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Joseph H. Capper acquired 200,000 shares of the stock in a transaction on Friday, May 2nd. The shares were acquired at an average price of $6.34 per share, with a total value of $1,268,000.00. Following the purchase, the chief executive officer now owns 529,530 shares in the company, valued at $3,357,220.20. This represents a 60.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 141,907 shares of company stock worth $1,112,580 in the last three months. 1.70% of the stock is currently owned by company insiders.

MiMedx Group Stock Performance

NASDAQ MDXG opened at $6.49 on Friday. The business’s 50-day moving average price is $6.83 and its 200 day moving average price is $8.04. The company has a market capitalization of $958.59 million, a PE ratio of 11.80 and a beta of 1.82. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, hitting analysts’ consensus estimates of $0.06. The company had revenue of $88.21 million for the quarter, compared to the consensus estimate of $86.32 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. On average, research analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on MDXG shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th. Wall Street Zen upgraded MiMedx Group from a “hold” rating to a “buy” rating in a research report on Friday.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.